BioSpace News Archive

Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, subsidiary HempMeds® announced today that the company has secured 100 new retail locations in Q1 2019, significantly outpacing its growth forecast for that time period.

Epitomee Medical, a bio-medical company developing treatments for the overweight and obese population, including treatment of glycemic control, weight reduction, and hypertension based on its unique swallowable-device gastric retention platform, announced the closing of an $8 million equity financing led by XT Hi-Tech.

NanoViricides, Inc. a company with novel platform technology to treat difficult and life-threatening viral diseases, reports that US FDA has responded to its request for a pre-IND meeting.

Strive Clinical Network (Strive), an East Texas network of Primary Care physicians, has produced exceptional first-year results in its care for members of the Employees Retirement System of Texas (ERS).

Cerevel Therapeutics, a biopharmaceutical company focused on developing new medicines to treat disorders of the central nervous system (CNS), today announced the publication of results from a Phase 2a study1 in Neurology demonstrating the anticonvulsant activity of CVL-865 (formerly PF-06372865), a novel α2/3/5-subtype selective GABAA positive allosteric modulator, in patients with photosensitive epilepsy (seizures triggered by visual stimuli).

FHI Clinical manages complex clinical research in resource-limited settings around the world

The researchers have been using Atomwise’s AI-powered in silico screening technology to develop therapeutic treatments for, among others, certain types of strokes, hand-foot-and-mouth disease, and an infection that causes reproductive failure in pigs.

International Isotopes Will Manufacture Azedra® and Other Iodine Products Under a Manufacturing And Supply Agreement

Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans to announce its operating results for the quarter ended March 31, 2019 after the market closes on Tuesday, April 23, 2019, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

xCella Biosciences announced a new antibody discovery research collaboration with Teva Pharmaceuticals Australia Pty Ltd. xCella will use its xPlorationTM single cell screening platform to identify rare antibodies against an undisclosed target of interest to Teva.